The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1

OBJECTIVE: There are few reports on the outcomes of 12-week paritaprevir, ombitasvir, and ritonavir (PTV/OBV/r) treatment in real-world clinical settings. We aimed to evaluate the efficacy and safety of 12-week treatment with ritonavir-boosted paritaprevir and ombitasvir in patients with hepatitis C...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Intern Med
Главные авторы: Miyasaka, Akio, Yoshida, Yuichi, Yoshida, Toshimi, Murakami, Akihiko, Abe, Koichi, Ohuchi, Ken, Kawakami, Tadashi, Watanabe, Daisuke, Hoshino, Takao, Sawara, Kei, Takikawa, Yasuhiro
Формат: Artigo
Язык:Inglês
Опубликовано: The Japanese Society of Internal Medicine 2018
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6207834/
https://ncbi.nlm.nih.gov/pubmed/29780135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.0810-18
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы